Inactive

MARKET RESEARCH PURPOSES ONLY NOT A REQUEST FOR PROPOSAL OR SOLICITATION The U.S. Food and Drug Administration (FDA), is conducting market research to support the Center for Biologics Evaluation Resea... MARKET RESEARCH PURPOSES ONLY NOT A REQUEST FOR PROPOSAL OR SOLICITATION The U.S. Food and Drug Administration (FDA), is conducting market research to support the Center for Biologics Evaluation Research (CBER) requirement for a ELISA Instrument (reader), MESO QuickPlex SQ 12. The FDA is seeking small business sources to determine the availability and capability of small business manufacturers or small businesses capable of supplying, and subsequently maintaining, a U.S. made product of a small business manufacturer or producer for the items described herein. Other than small business concerns are also encouraged to submit capability statements. The following information is provided to assist the FDA in conducting Market Research to identify potential contractors for this effort. The associated North American Industry Classification System (NAICS) Code is-334516- Analytical Laboratory Instrument Manufacturing; Small Business Size Standard is 1,000 employees. Purchase of one (1) brand name or equal MSD ELISA Instrument (reader), MESO QuickPlex SQ 12 for the Center for Biologics Evaluation and Research (CBER), Office of Tissue and Advanced Therapies (OTAT), Division of Plasma Protein Therapeutics (DPPT), Hemostasis Branch (HB). Part of this market research effort is to determine that only this name brand instrument can meet CBER’s requirement. Alternative solutions will be considered insofar as any such alternate system and/or system components meet the minimum brand name or equal technical requirements. Background The CBER/OTAT/DPPT/HB regulates Plasma Protein Therapeutics intended to treat patients with abnormal hemostasis in particular, deficiencies in blood coagulation, and performs research in this area. The laboratory studies biochemistry of blood coagulation involving factor VIII (FVIII) which deficiency results in life-threating bleeding known as Hemophilia A. In particular, the study of (i) structure and functions of FVIII related to plasma clearance of FVIII that is relevant to FDA review and generation of longer-acting FVIII products, and product-related impurity in therapeutic FVIII products relevant to increasing purity of FVIII products. Altogether, these directions are related to generation of more efficient and safer FVIII products to improve treatment of Hemophilia A. Purchase of MSD ELISA Instrument or equal will allow detection and quantitation of FVIII and its experimental variants with extremely high sensitivity and selectivity (specificity) in a wide dynamic range in various complex matrixes, containing numerous interfering compounds, such as cell culture media and both human and model animals (mice etc.) plasma, as the system uses a unique proprietary electrochemiluminescence protein detection. The MSD ELISA Instrument or equal required for the project is needed to measure very low concentrations of FVIII in both cell culture upon protein expression and animal plasma in FVIII pharmacokinetics studies, as no other methodology, including common types of ELISA applications, can measure protein content at such conditions with required sensitivity. Also, the methodology allows measuring concentrations of other proteins related to different research projects, and study aims. Minimum Performance Requirements Sensitivity: At least 10-100 pg of protein antigen/mL in particular assays Specificity: The assay must be based on Electrochemiluminescence (ECL) principle Dynamic Range: Wide linearity such as that in the range of 104-105 concentration units Plate read time (based on ECL principle): Not more than 2 min Size: Compact, not more than 14 x 25 x 22 (in). Instrument larger than this available lab space may be considered unacceptable if lab space is not available. All accessories for startup and assay control (computer system and software, etc.) System must have full 1-year warranty following installation. System must come up with onsite set up and appropriate familiarization. Vendor must provide application, operation and service manuals. Vendor must provide unlimited free telephone, e-mail and fax technical support for one-year starting from date of government acceptance. Installation, training and additional system requirements The components and/or equipment shall be a newly manufactured, not used and refurbished, or previously used for demonstration. FOB Point destination to include inside delivery, installation, and clean-up of area after installation. The system shall be a turn-key solution i.e., the contractor shall be responsible for providing all hardware, components, software, and that otherwise required to meet these specifications, the FDA’s stated need and shall be fit for intended purpose. The systems shall be delivered with all necessary supplies and accessories required for installation and start-up. The vendor shall demonstrate upon installation that the item meets all performance specifications. The instrument shall not be accepted until those performance specifications have been met. The contractor shall provide all labor, travel, and tools to install the equipment at the address provided herein, to include shipping. The contractor shall provide guidance on pre-installation site requirements. The contractor shall demonstrate upon installation that the item meets all performance specifications. The instrument shall not be accepted until those performance specifications have been met. Equipment familiarization training for up to 3 people shall be provided at the installation site. The familiarization shall include but not be limited to routine maintenance, method setup, and sample analysis. Records and Reports The Contractor shall, commensurate with the completion of installation of new equipment provide the end-user of the equipment with a copy of installation report identifying the equipment name, manufacturer, model number, and serial number of the equipment being installed and updated software versions. In addition, vendor must provide a report of installation and operation verifying functionality of instrument for intended use. FOB Point Destination. All items shall include shipping, handling and in-side delivery to the destination identified herein. Delivery, installation and staff familiarization training shall occur within the contractor’s normal manufacturing lead times for these items but shall be no more than 90 calendars days from date of award. FOB Point of Delivery for Services and Supplies will be the FDA located at 10903 New Hampshire Ave, Building 52/72, Room 4208, Silver Spring, MD 20993. Alternative solutions will be considered insofar as any such alternate system and/or system components meet the minimum brand name or equal technical requirements. The offeror shall furnish sufficient technical information necessary for the Government to conclusively determine that the offered products/services and components meet the technical requirements identified above. Though the target audience is small business manufacturers or small businesses capable of supplying a U.S. made product of a small business manufacturer or producer all interested parties may respond. At a minimum, responses shall include the following: Business name, Unique Entity ID (SAM) number, business address, business website, business size status (i.e., SB, VOSB, SDVOSB, HUBZone SB, SDB, WOSB, LB), point of contact name, mailing address (if different from business address), phone number and email address (Provide this same information if responding to provide a product manufactured by another firm); Sufficient descriptive literature that unequivocally demonstrates that offered products and services can meet the above requirements. All descriptive material necessary for the government to determine whether the service/product offered meets the technical requirements including: technical specifications, descriptive material, literature, brochures and other information, which demonstrates the capabilities of the contractor to meet the requirement. Past performance information within the last three years for the manufacture and/or sale in which the offeror has provided same or substantially similar system solutions and used for same or near-same applications as set forth herein. For each past performance reference include the date of sale, description, dollar value, client name, client address, client point of contact name, client point of contact mailing address (if different from that provided for client), client point of contact phone number, client point of contact email address, and name of the manufacturer (to include Unique Entity ID (SAM) number and size status) if not the respondent. If applicable, identification of the firm's GSA Schedule contract(s) by Schedule number and SINs that are applicable to this potential requirement. Detailed list of items included and not included on the GSA contract to meet this requirement. If applicable, identification of Best in Class (BIC) contract information or other Government-wide or HHS-wide contracts that the equipment/service is available on. Provide information if any of these specifications are too restrictive. No response will be considered that the listed specifications are adequate in a competitive environment. If a large business, identify the subcontracting opportunities that would exist for small business concerns; Standard commercial warranty and payment terms; Provide place of product manufacture or service performance and any other applicable information to enable review and analysis pertaining to the Buy American statute and requirements relating to Made in America in the event a nonavailability waiver request through the MIAO Digital Waiver Portal is needed; and Though this is not a request for quote, informational pricing is encouraged. The government is not responsible for locating or securing any information, not identified in the response. The Government encourages any comments and/or suggestions from any interested party, regarding the specifications. While the Government will not respond directly to your comments and/or suggestions; we will consider them as we finalize the specifications in preparation for the forthcoming solicitation. Interested Parties shall respond with capability statements which are due by email to the point of contact listed below on or before June 15, 2022 by 13:00 hours (Central Time in Jefferson, Arkansas) to nick.sartain@fda.hhs.gov. Reference CBER-2022-112971. Notice of Intent Responses to this sources sought announcement will assist the Government in determining whether or not any future requirement similar to this one should be set aside for small business, made available to full and open competition or procure through sole-source acquisition procedures. Disclaimer and Important Notes This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in sam.gov. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).